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Aims Blood pressure (BP) responses during dobutamine stress echocardiography (DSE) have not been systematically studied.
Consequently, it is not knownwhat constitutes a normal or an abnormal BP response to dobutamine stress.We sought
to define the typical BP response during DSE of patients not known to have cardiovascular disease.
Methods and
results
Of 24 134 patients who underwent DSE from November 2003 to December 2012 at Mayo Clinic, Rochester, MN,
2968 were selected for inclusion in this retrospective study. Excluded were patients with a history of hypertension,
diabetes, or coronary artery disease, and those taking vasoactive medications. Patients who had baseline and/or
stress-induced wall motion abnormalities were also excluded. The distribution of the study population’s BP responses
during DSE was Gaussian; we defined cut-point values for normative BP responses at 2 SD for each decade of age and
for the whole study population. During DSE, systolic BP (SBP) increased from baseline to peak stress (D
+2.9+ 24 mmHg, P, 0.0001) and diastolic BP (DBP) decreased (D 27.4+ 14 mmHg). BP changes were age and
sex dependent; men and younger patients had greater DSBP and lesser DDBP, compared with women and older pa-
tients. Patients who received atropine had higher peak BP values than patients who did not receive atropine, due to
greater DSBP (+7.4+ 26 vs. 20.5+ 22 mmHg, P, 0.0001) and lesser DDBP (24+ 14 vs. 29.7+ 12 mmHg,
P, 0.0001). This atropine effect was present in men and women, and was more pronounced in younger patients.
The normative peak SBP values ranged from 82 to 182 mmHg.
Conclusion BP responses during DSE vary and depend on patients’ age, gender, and the use of atropine. We describe the typical BP
responses seen during DSE and report normative reference values, which can be used for defining normal and abnormal
BP responses to dobutamine stress.
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Introduction
Dobutamine stress echocardiography (DSE) is a well-established
diagnostic and prognostic stress imaging test, used for the evaluation
of patients with suspected or established coronary artery disease.1–4
Although dobutamine is generally well tolerated and safe,4 –10 ab-
normal blood pressure (BP) responses can occur and may lead to
early discontinuation of the test.1,2 Even though DSE has been per-
formed for longer than 25 years at many institutions, patterns of BP
responses during DSE have not been systematically studied. In one
study, published 20 years ago, dobutamine/atropine stress echocar-
diography was performed on 14 young healthy adult subjects.11 In
prior studies, investigators used different BP cut-points to describe
an abnormal BP response during DSE.8,12 – 16 These cut-points
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varied and were arbitrarily established or extrapolated from exer-
cise stress data. Additionally, patients in those studies had hyperten-
sion, diabetes, or established coronary disease. These conditions
and their treatments can have an effect on BP responses during
DSE and on the stress echocardiographic findings. There are few
published studies examining the effect of atropine administration
on BP responses during DSE.17,18 Normative reference values for
BP responses during DSE are needed to reach agreement on what
the definition(s) of abnormal BP responses to dobutamine stress
should be.
We sought to define the typical BP response to DSE in a large
contemporary series of patients not known to have cardiovascular
disease who had normal findings on DSE.We also evaluated the im-
pact of the addition of atropine on BP responses during DSE. Finally,
we propose cut-point values for normative systolic blood pressure
(SBP) and diastolic blood pressure (DBP) responses to be used as
reference values for future studies.
Methods
Study population
All patients (n ¼ 24 134) who underwent DSE at Mayo Clinic, Roches-
ter, MN, from November 2003 to December 2012 were candidates for
this retrospective study. Patients’ clinical characteristics were abstracted
from their medical records by specially trained registered nurses at the
time of their stress echocardiograms. These data, along with each pa-
tient’s baseline and stress clinical and echocardiographic data, were en-
tered into an institutional stress echocardiography research database.
Of the patients, 1223 patients did not give permission to use their med-
ical records for research purposes.We excluded patients who had a his-
tory of hypertension (n ¼ 16 488), diabetes mellitus (n ¼ 6619),
coronary artery disease (defined as a history of myocardial infarction,
prior percutaneous coronary revascularization or coronary artery by-
pass graft surgery) (n ¼ 5810), or at least moderate valvular heart dis-
ease (n ¼ 952). Patients taking b-blockers, calcium-blockers, or
inhibitors of the renin–angiotensin–aldosterone system were ex-
cluded, as were patients with baseline and/or stress-induced echocar-
diographic regional wall motion abnormalities (n ¼ 6834). After
exclusions, the study population comprised 2968 patients.
DSE protocol
After a 3-h fast, dobutamine was administered intravenously by an infu-
sion pump at a starting dose of 5 mg/kg/min. After 3 min, the dose was
increased to 10 mg/kg/min and then by 10 mg/kg/min every 3 min, up to
a maximal dose of 40 mg/kg/min if needed. Intravenous atropine was ad-
ministered to patients who did not achieve their target heart rate (HR),
which was 85% of age-predicted maximal HR,1 calculated by subtracting
the age of the patient from 220. Atropine was administrated in 0.25 mg
dose increments every 1 min, up to a maximum of 2 mg if necessary.18–20
Atropine was given at the end of the 20 mg/kg/min stage if the HR was
,90 bpm, at the end of the 30 mg/kg/min stage if ,70% of age-
predicted maximal HR, and at the end of the 40 mg/kg/min stage if
,85% of age-predicted maximal HR. The criteria for terminating the
test were those recommended in the guidelines1,2 and included severe
hypertension (SBP . 240 or DBP . 120 mmHg) and hypotension
(SBP, 90 mmHg if associated with symptoms).
BP measurements
Systolic and diastolic BP measurements were made by specially trained
registered nurses using a sphygmomanometer with patients in the left
lateral decubitus position: at baseline and every 3 min during the test,
near or at peak stress and in recovery. DSBP was defined as SBP at
peak stress minus SBP at baseline. DDBP was defined as DBP at peak
stress minus DBP at baseline. Peak SBP and peak DBP were defined
as SBP and DBP at peak stress.
Echocardiographic analysis
Two-dimensional digitized and videotaped echocardiographic images
were acquired at baseline, during the stress test, and in recovery, ac-
cording to a previously published protocol.21 The left ventricular ejec-
tion fraction (EF) was determined by either visual assessment or a
modification of the Quinones method.22 Wall motion was assessed
with a 16-segment model proposed by the American Society of
Echocardiography.23
Statistical analysis
Clinical and echocardiographic data were summarized using means and
standard deviations (SDs) for continuous variables and percentages for
dichotomous or qualitative variables. Data are presented according to
sex, age, and usage of atropine in addition to dobutamine. BP values
at every stage of dobutamine infusion were also summarized. T-tests,
x2 tests, and analysis of variance (ANOVA) were used when appropri-
ate. Paired sample t-test and ANOVA for paired data were used to com-
pare intragroup differences. A significance level of 0.05 was considered
statistically significant. Cut-point values were defined based on the dis-
tribution of peak systolic and diastolic BP values, which was normal
(Gaussian) for both variables. We added 2 SDs for the upper limit
and subtracted 2 SDs for the lower limit. A logistic regression analysis
was used to identify predictors of hypertensive and hypotensive SBP re-
sponses during DSE. The variables considered were age, sex, baseline
SBP, atropine usage, EF at baseline, and EF at peak stress.
Results
Of the 2968 patients, 1335 (45%) underwent DSE for pre-operative
assessment, 1283 (43%) for assessment of chest pain or dyspnoea,
and 350 (12%) for coronary artery disease screening or abnormal
electrocardiography. The mean age of the study population was
62+ 13 years, and 1658 (56%) were women. The ethnicity of the
study population, by self-reporting, was as follows: 2644 werewhite,
48 black, 27 Asian, 11 native-American, and 219 other or not
known.
BP response
During dobutamine infusion, the SBP response was ‘flat’
(,10 mmHg increase or decrease compared with baseline) in
1118 patients (38%). The SBP increased by 10 mmHg or more in
1064 patients (36%), and decreased by 10 mmHg or more in 786 pa-
tients (26%). Overall, the SBP increased slightly from baseline to
peak stress, the DBP andmean BP decreased, and the pulse pressure
increased (Table 1).
Compared with men, women had less change in SBP during DSE
(DSBP +1.1+ 23 for women vs. +5+ 24 mmHg for men,
P, 0.0001) and greater change in DBP (DDBP 28+ 13 for
women vs. 26.7+ 13 mmHg for men, P ¼ 0.016).
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The degree of BP change during dobutamine infusion was age re-
lated (Table 2). The DSBP of younger patients was greater than that
of older patients, with a downward trend across decades and nega-
tive values in patients 70 years and older. Younger patients had a
lesser decrease in DBP values than older patients.
BP response and atropine administration
A total of 1264 (43%) patients received atropine. Men received
atropine more frequently than women (51 vs. 37%, P, 0.0001).
Patients who received atropine had significantly higher peak HR
and BP values, compared with patients who did not receive atropine.
DHR was higher in patients who received atropine (73+15 bpm),
compared with patients who did not (61+ 15, P, 0.0001). The
DSBP values were +7.4+ 26 for patients who received atropine
and 20.5+ 22 mmHg (P, 0.0001) for patients who did not;
the corresponding DDBP values were 24.4+ 14 and 29.7+
12 mmHg, respectively (P, 0.0001). This effect of atropine was
present in men (DSBP and DDBP +8.6+ 26 and 24.4+ 15 with
atropine vs. +1.7+23 and 29+ 12 without atropine) and in wo-
men (+6.3+ 25 and 24.3+ 14 with atropine vs. 21.9+ 21 and
210+ 12 without atropine). Atropine was administrated to 64%
of patients ,50 years, to 55% of patients between 50 and 59 years,
to 39% of patients between 60 and 69 years, and to 25% of patients
≥70 years. There were greater SBP changes in younger patients
who received atropine and lesser DBP changes in all age groups
who received atropine (Figure 1).
HR response, symptoms, and ECG results
A total of 2196 patients (74%) achieved target HR; 563 patients
(19%) and 227 patients (7%) achieved 80 to 84.9% and ,80% of
age-predicted maximal HR, respectively. The patients who did not
achieve target HR were younger (57+ 12 vs. 64+ 13 years,
P, 0.0001). Although the peak SBP achieved was lower in patients
who did not achieve target HR (128+ 27 vs. 134+ 23 mmHg,
P, 0.0001), the upper ranges (2 SDs) for the two subgroups
were comparable (182 vs. 180 mmHg). Similarly, although the
peak DBP was lower (67+ 15 vs. 69+ 13 mmHg, P, 0.0015) in
patients who did not achieve target HR, the upper ranges (2 SDs)
for the two subgroups were comparable (97 vs. 95 mmHg).
During DSE, chest pain developed in 12% of patients, dyspnoea
in 8%, headache in 11%, nausea in 9%, and shivering or anxiety in
19%. Overall, 93% of patients had stress ECG results that were
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Blood pressure, heart rate, rate-pressure
product, and ejection fraction responses during DSE
Baseline Peak stress Delta
SBP (mmHg) 129+19 132+25 +2.9+24
DBP (mmHg) 76+12 68+14 27.4+14




Heart rate (bpm) 72+12 138+12 66+16
Rate-pressure
product
9256+2068 18 211+3876 8952+4100
EF (%) 62+5 75+4 13+4
All P-values at baseline vs. peak stress: ,0.0001.
DBP, diastolic blood pressure; EF, ejection fraction; SBP, systolic blood pressure.
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Table 2 Blood pressure and heart rate responses during DSE, by age groups
Age (years) <50 50–59 60–69 ≥70 P-value
No. of patients 478 714 873 903
Baseline SBP (mmHg) 122+17 123+17 129+19 138+19 ,0.0001
Peak SBP (mmHg) 137+25 130+25 131+25 133+23 ,0.0001
Delta SBP (mmHg) +16+23 +6+22 +1+23 26+23 ,0.0001
Baseline DBP (mmHg) 76+12 75+12 76+12 76+11 ns
Peak DBP (mmHg) 74+15 70+14 67+14 66+12 ,0.0001
Delta DBP (mmHg) 22+15 26+13 29+13 210+12 ,0.0001
Baseline PP (mmHg) 46+11 49+12 53+13 62+15 ,0.0001
Peak PP (mmHg) 64+17 60+18 64+19 66+18 ,0.0001
Delta PP (mmHg) +18+17 +12+17 +10+18 +4+19 ,0.0001
Baseline MBP (mmHg) 91+13 91+13 94+13 97+12 ,0.0001
Peak MBP (mmHg) 95+17 90+16 88+16 88+14 ,0.0001
Delta MBP (mmHg) +4+16 22+14 25+15 29+14 ,0.0001
Baseline HR (bpm) 73+13 73+12 71+12 70+11 ,0.0001
Peak HR (bpm) 151+11 142+9 135+9 129+10 ,0.0001
Baseline RPP 8848+2153 8960+1946 9248+2101 9714+1997 ,0.0001
Peak RPP 20 759+4269 18 524+3923 17 638+3460 17 170+3333 ,0.0001
Delta RPP 11 909+4403 9555+3996 8387+3617 7460+3516 ,0.0001
DBP, diastolic blood pressure; HR, heart rate; MBP, mean blood pressure; ns, non-significant; PP, pulse pressure; RPP, rate-pressure product; SBP, systolic blood pressure.
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negative for ischaemia, 2% were positive for ischaemia, and 5%
were uninterpretable. Complications were rare; 19 patients devel-
oped sustained supraventricular tachycardia. All of these patients
went back into sinus rhythm after administration of intravenous
metoprolol or esmolol. Another 16 patients developed atrial fib-
rillation. Eight of these patients went back into sinus rhythm during
extended recovery period monitoring after administration of an
intravenous b-blocker. The other eight patients had HR slowing;
at follow-up within 24 h, sinus rhythm had returned spontaneously
in seven patients and one patient underwent direct current cardi-
oversion. There were no cases of sustained ventricular tachycar-
dia, ventricular fibrillation, or myocardial infarction.
Patients receiving dobutamine dose of
40 mg/kg/min
A total of 1449 patients received the full dobutamine dose of 40
mg/kg/min. Of these patients, 855 (59%) also received atropine.
There was a positive DSBP from baseline to peak dose (+4+ 25
mmHg, P , 0.0001) and negative DDBP (27+ 14 mmHg,
P, 0.0001), resulting in slightly negative mean BP (23+ 16
mmHg, P, 0.0001). DSBP was significantly greater in men than in
women (+6+25 vs. +2+ 25 mmHg, P ¼ 0.016), and in younger
patients than in older patients. There was a significant increase in
DSBP at a dobutamine dose of 10 mg/kg/min. The DSBP increase
persisted at higher dobutamine doses in patients who received at-
ropine, but not in patients who did not receive atropine (Figure 2).
There was a progressive downward trend in DDBP in both
groups, but the extent of reduction at each dobutamine stage
was lower in patients who received atropine, compared with
Figure 1 Blood pressure response during DSE, by age and the
use of atropine. DSBP was higher and DDBP was lower in patients
who received atropine, compared with patients who did not. BP
values were higher in younger patients. Data presented as mean
value+ 1 SD. DDBP, change in diastolic blood pressure; DSBP,
change in systolic blood pressure.
Figure 2 Blood pressure and HR responses in patients who received a dobutamine dose of 40 mg/kg/min, by the use of atropine. Changes from
baseline, during each dobutamine stage. Data presented as mean value+1 SD. DDBP, change in diastolic blood pressure; DSBP, change in systolic
blood pressure; HR, heart rate.
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patients who did not. The HR increased progressively in both
groups. The rise was significantly slower in patients who received
atropine (Figure 2).
Patients who received atropine developed symptoms more fre-
quently than patients who did not receive atropine, including chest
pain (17 vs. 8%, P, 0.0001), headache (13 vs. 9%, P ¼ 0.03), nausea
(15 vs. 8%, P ¼ 0.0003), and shivering or anxiety (25 vs. 17%,
P ¼ 0.0003). The frequency of dyspnoea was the same in both
groups (9%).
Normative BP responses during DSE
Based on the Gaussian distribution of the BP response to DSE, cut-
point values for normative BP response to DSE were generated,
both for the whole study population and for each decade of age
(Table 3). To facilitate the utilization of these cut-point values in clin-
ical practice, we propose using two unique upper values (one systol-
ic and one diastolic) and two unique lower values (one systolic and
one diastolic), obtained from the overall study population. The pro-
posed normative SBP value at peak stress ranges from 82 to
182 mmHg. The proposed normative DBP value at peak stress
ranges from 40 to 96 mmHg.
Predictors of abnormal BP response
As defined by the peak SBP, 66 patients had a hypertensive response
and 51 had a hypotensive response. Multivariate predictors of a
hypertensive response were male sex [odds ratio (OR) 2.6, confi-
dence interval (CI) 1.5–4.5, P ¼ 0.003], age (OR 0.7 per 10-year in-
crease, CI 0.5–0.8, P, 0.001), atropine usage (OR 2.6, CI 1.5–4.6,
P ¼ 0.0005), and baseline SBP (OR 1.6 per 10 mmHg increase, CI
1.4–1.9, P, 0.0001). The only independent predictor of a hypoten-
sive response was baseline SBP (OR 0.5 per 10 mmHg increase, CI
0.4–0.6, P, 0.0001). Left ventricular EF at peak stress was not a
multivariate predictor of a hypotensive response.
Discussion
The typical BP response during DSE in a population without known
cardiovascular disease and not on any vasoactive medication con-
sists of a slight increase in SBP and a decrease in DBP. BP response
is greater in men than in women, and in younger than in older
patients, and is most pronounced in patients who receive atropine,
regardless of sex and age. On the basis of these results, we pro-
pose novel normative values for BP response to dobutamine
stress.
BP and HR response
Dobutamine is a sympathomimetic agent that increases myocardial
oxygen consumption through predominantly inotropic and chrono-
tropic effects (b-1-adrenergic cardiac receptor agonism).6,24,25 It
also has weaker peripheral actions, mostly as a vasodilator
(b-2-adrenergic receptor agonism) promoting a slight baroreflex-
mediated further increase in HR, and minimally as a vasopressor
(a-1-adrenergic receptor agonism).6,14,24 The net effect on BP is
the result of increased myocardial contractility combined with the
sum of opposing peripheral vascular effects. In our study population,
a predominant dobutamine-induced vasodilating effect was likely
the main mechanism for the slight decrease in DBP we observed.
This effect is likely counterbalanced in systole by a dobutamine-
induced increase in cardiac output, resulting in a slight increase in
SBP. In addition, we observed a significant increase in HR and rate-
pressure product. Similarly, in prior animal model studies, rate-
pressure product increased but mean aortic pressure did not
change significantly with dobutamine infusion.26,27 Healthy young
men who received both dobutamine and atropine prior to positron
emission tomography had an increase in SBP, DBP, and rate-
pressure product.28 Prior clinical studies described an overall
increase in DBP during DSE13,15 and an increase in SBP that was
greater than that of our study.3,4,13,15,16 These studies included
patients with cardiovascular co-morbidities whowere on vasoactive
medications, factors that can influence the cardiovascular response
to dobutamine stress. For example, patients who have hypertension
often have elevated peripheral vascular resistance;29 an increase in
cardiac output by dobutamine infusion may not be offset by prompt
peripheral vasodilation in a subset of these patients. Additionally, the
modest a-1-adrenergic vasoconstrictive effect of dobutamine may
be exaggerated in hypertensive patients with sympathetic nervous
system hypersensitivity. b-Adrenergic receptor antagonism with
b-blocker therapy may result in an exaggerated BP response to do-
butamine and atropine in susceptible patients; further studies are
needed to address this hypothesis.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Cut-points for normative blood pressure response during DSE, based on peak SBP and peak DBP means +2
SDs, overall and by age
Age (years) <50 50–59 60–69 ≥70 Overall
Peak SBP (mmHg) 137+25 130+25 131+25 133+23 132+25
+2 SD 187 180 181 179 182
22 SD 87 80 81 87 82
Peak DBP (mmHg) 74+15 70+14 67+14 66+12 68+14
+2 SD 104 98 95 90 96
22 SD 44 42 39 42 40
DBP, diastolic blood pressure; SBP, systolic blood pressure; SD, standard deviation.
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We found that women had lower peak SBP and DBP values during
DSE than did men, whether atropine was administrated or not.
These findings were consistent with those of a prior study.30 Wo-
men who did not receive atropine had negative values of DSBP, em-
phasizing the low likelihood of women developing high SBP in
response to dobutamine. In contrast, other studies reported no
sex differences in BP response or greater SBP increases during
DSE in women than in men.3,31 However, in contrast to the present
study, in those studies women had greater baseline SBP values than
men or patients were taking multiple cardiovascular drugs. The pre-
cise mechanism underlying these sex differences in BP response
during DSE is unclear, but arterial BP dissimilarities between men
and women are recognized in the literature.32
Age differences
In the present study, the increase in SBP during DSE was greater in
younger than in older patients and tended to decline with age, be-
coming a SBP decrease in patients ≥70 years of age. Conversely, the
DBP decrease during DSE was greater with advancing age. As a re-
sult, older patients had lower BP in response to DSE, consistent with
previous studies.9,25 A clear explanation underlying difference of BP
responses between ages has not been defined and different mechan-
isms likely contribute. Age-related changes in adrenergic and baror-
eflex responsiveness have been demonstrated33–35 and include a
diminished stress-induced HR increase in the elderly.34 This could
influence at least SBP changes, by a lesser effect on cardiac output
compared with younger patients. Furthermore, it is known that vas-
cular compliance decreases with age, leading to a lower effective-
ness in compensatory BP changes, along with sharp falls in DBP in
the elderly.36 Further information regarding cardiac output and ar-
terial stiffness would be needed to fully explain these BP responses.
Effect of atropine
Atropine use during DSE is safe and enhances the diagnostic accur-
acy of the test by contributing to an increase in HR and myocardial
oxygen demand.18,19,37 Atropine, at the doses used during DSE, ex-
erts its effect through a parasympatholytic effect (competitive antag-
onist of muscarinic acetylcholine receptors) at the cardiac level,37
countering the decrease in HR mediated by vagal tone. Studies on
animals demonstrated that atropine has no direct effects on periph-
eral vasculature.38 The present study shows that patients who re-
ceived atropine during DSE had higher peak BP values than
patients who did not receive atropine, regardless of sex and age.
This corresponded to a more pronounced DSBP from baseline to
peak stress and a less pronounced negative DDBP. Peak BP values
were especially higher in younger patients, who received atropine
more often than older patients. The difference in DBP values be-
tween patients who received atropine and patients who did not
were statistically significant at a dobutamine dose of 20 mg/kg/min,
corresponding to the earliest time at which atropine was adminis-
tered. Given the absence of atropine effect on the peripheral vascu-
lature, its effects on BP would have to be due to its positive
chronotropic effect. It is also possible that the higher frequency of
symptoms that developed in patients receiving atropine contributed
to the higher BP values. Few, but consistent hints of higher BP values
in patients who received atropine, compared with patients who did
not, have been reported in previous DSE studies.10,13
BP response cut-points
The expected or typical BP responses during DSE have not been
systematically defined, and the cut-points used in previous studies
to describe abnormal BP responses were arbitrarily estab-
lished.8,12–16 On the basis of our results, we propose novel BP re-
sponse cut-points for DSE, derived from a large population of
patients without known cardiovascular disease and who were not
on vasoactive medications. These data may help facilitate broad
agreement regarding what the definition(s) of an abnormal BP re-
sponse to dobutamine stress should be. Moreover, they constitute
criteria that can be used for future studies regarding the clinical im-
plications of abnormal BP responses during DSE.
Limitations
A limitation is the challenge of defining ‘normal’ BP responses during
DSE in patients who are referred for testing. It is unlikely, however,
that a study defining the expected or normal BP responses during
DSE in healthy adult volunteers of all ages will ever be performed
on a large scale. In the present study, it is possible that some patients
had coexisting medical conditions that could have affected their BP
responses to DSE even though all patients with known cardiovascu-
lar disease, those taking vasoactive medications, and those who had
abnormal stress echocardiograms were excluded. A complete
explanation of the mechanisms underlying BP pressure variations
is beyond the scope of this study.
Conclusions
This is the first study to define typical BP responses during DSE in a
large population of adult patients of all ages not known to have car-
diovascular disease and not taking vasoactive medications. The ex-
istence of cut-off values for normal BP responses, rigorously
established in this study, should aid in the recognition of abnormal
BP responses during DSE. Moreover, these reference values should
serve as a robust foundation for future studies, which could be
aimed at answering questions that remain regarding the clinical im-
plications of abnormal BP responses during DSE.
Conflict of interest: None declared.
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